Abbott Labs Stock Price, News & Analysis

Abbott (NYSE: ABT) announced Lingo, its over-the-counter continuous glucose monitor and app, is now available on Android, expanding access beyond iOS in the U.S. and U.K.

Lingo is intended for adults 18+ not using insulin and offers real-time glucose data and a daily metric, Lingo Count, to quantify glucose spikes. Abbott reported that reducing Lingo Count over about three months halves time above the healthy range and lowers average glucose by 10%. Real-world data showed protein supplementation days had 15% lower odds of glucose spikes and a 2 mg/dL average glucose reduction ( 18% odds and 3 mg/dL reduction among people with obesity).

Abbott (NYSE: ABT) and the Big Ten reported that the second annual "We Give Blood" drive (Aug. 27–Dec. 5, 2025) produced 83,043 donations, a 319% increase versus 2024, and could help save up to 250,000 lives. The University of Wisconsin led with 15,476 donations and will receive a $1 million Abbott award to advance student or community health. Student donors rose 168%, with 92% of participants saying they are likely to donate again. The campaign aimed to address a national blood shortage and boost younger donor participation.

Abbott (NYSE: ABT) on Dec. 4, 2025 launched two Ensure Max Protein shakes aimed at muscle health: Ensure Max Protein 42g for active adults (42 g protein, 23 vitamins/minerals, 2 electrolytes, 2 g sugar, 220 calories) and Ensure Max Protein 2 in 1 Muscle Support for older adults (30 g protein, 1.5 g CaHMB, 26 vitamins/minerals). Abbott cited muscle loss after age 40 and described HMB research spanning 25+ years. Real-world data from >9,500 users of Abbott's Lingo continuous glucose monitor found 15% lower odds of elevated glucose on days users consumed protein shakes. The products are exclusive at Walmart through March 2026, with wider retail distribution beginning April 2026.

Abbott (NYSE: ABT) agreed to acquire Exact Sciences (NASDAQ: EXAS) for $105 per share, implying approximately $21 billion equity value and an estimated $23 billion enterprise value; Abbott will absorb about $1.8 billion of Exact Sciences net debt. Exact Sciences is projected to generate more than $3 billion in revenue this year with high‑teens organic growth and brings leading assets including Cologuard, Oncotype DX, Oncodetect and Cancerguard. Abbott expects the deal to be immediately accretive to revenue growth and gross margin. Closing is expected in Q2 2026, subject to shareholder and regulatory approvals.

Abbott (NYSE: ABT) and Hallmark Channel partner on a new holiday film, "The More the Merrier", which premieres Friday, Nov. 28, 2025 at 8 p.m. ET/PST and streams on Hallmark+ the following day. The movie features real members of Abbott HeartMates — a support community for people affected by heart conditions — and includes cameos by HeartMates ambassador Damar Hamlin.

The story centers on a 14-year-old heart patient inspired by HeartMates member Zeke Mankins; other featured members include Tony Daly, Jaden Hartley, Rian Krauth, and MacKenzie Maddry. Abbott cardiologists consulted on the script for medical accuracy. Safety links for specific Abbott devices are provided for U.S. audiences.

Abbott (NYSE: ABT) reported 3Q25 sales $11.37B, up 6.9% reported and 5.5% organic (or 7.5% organic excluding COVID‑19 tests). 3Q GAAP diluted EPS was $0.94; adjusted diluted EPS was $1.30. Reported operating margin was 18.1%; adjusted operating margin was 23.0% (+40 bps).

Medical Devices led growth: +14.8% reported and Diabetes Care CGM sales were $2.0B (+20.5% reported). Diagnostics declined: −6.6% reported (COVID testing sales $69M vs. $265M prior year). Abbott reaffirmed full‑year 2025 organic sales guidance and narrowed adjusted EPS range to $5.12–$5.18.

Abbott (NYSE:ABT) has scheduled its third-quarter 2025 financial results announcement for Wednesday, October 15, 2025, before market opening. The company will host a live earnings conference call at 8 a.m. Central time (9 a.m. Eastern). Investors can access the webcast through Abbott's Investor Relations website. An archived version of the call will be made available later the same day.

Abbott (NYSE: ABT) has announced its 407th consecutive quarterly dividend of 59 cents per share. The dividend will be payable on November 17, 2025, to shareholders of record as of October 15, 2025.

The company has demonstrated remarkable dividend consistency, having increased its dividend payout for 53 consecutive years. Abbott's commitment to dividend growth has earned it a place in the S&P 500 Dividend Aristocrats Index, which recognizes companies with at least 25 years of consecutive dividend increases.

Abbott (NYSE:ABT) has received CE Mark approval for an expanded indication of its Navitor™ TAVI system to treat patients with symptomatic, severe aortic stenosis who are at low or intermediate surgical risk. This expansion, supported by the VANTAGE trial data, makes Navitor available across all surgical risk categories in Europe.

The VANTAGE study demonstrated excellent outcomes, including a low 2.3% rate of all-cause mortality or fatal stroke/stroke with disability, no moderate or greater PVL at 30 days, and a 97% technical success rate. Additionally, the European Society of Cardiology announced updated guidelines upgrading recommendations for Abbott's MitraClip™ and TriClip™ therapies for treating heart valve diseases.